title: The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
abstract: The aim of this study was to determine the influence of acute (single) and chronic (once daily for 7 consecutive days) treatments with atorvastatin and fluvastatin on the anticonvulsant potential of three antiepileptic drugs: carbamazepine, phenytoin and valproate in the mouse maximal electroshock-induced seizure model. Additionally, the effects of acute and chronic administration of both statins on the adverse effect potential of three antiepileptic drugs were assessed in the chimney test (motor performance) and passive avoidance task (long-term memory). To evaluate the pharmacokinetic characteristics of interaction between antiepileptic drugs and statins, the total brain concentrations of antiepileptic drugs were estimated with the fluorescence polarization immunoassay technique. Results indicate that atorvastatin at doses up to 80mg/kg in chronic experiment attenuated the anticonvulsant potential of carbamazepine by increasing its ED(50) value against maximal electroconvulsions. Acute fluvastatin (80mg/kg) enhanced the anticonvulsant potential of carbamazepine and valproate by decreasing their ED(50) values. Acute fluvastatin (80mg/kg) also markedly increased the total brain carbamazepine concentration by 61% in a pharmacokinetic reaction. Atorvastatin (acute and chronic) and fluvastatin (chronic) in combinations with valproate impaired long-term memory in mice. Both statins in combinations with all three antiepileptic drugs had no impact on their adverse effects in the chimney test. Based on this preclinical study, one can conclude that chronic administration of atorvastatin reduces the anticonvulsant action of carbamazepine and acute fluvastatin can enhance the anticonvulsant potency of the carbamazepine and valproate. The former interaction was pharmacokinetic in nature.
authors: Department of Pathophysiology, The Medical University, of Lublin, Poland. kstepien@doctors.org.uk
authors: Karolina M
authors: KM
authors: Stepien
authors: Michal
authors: M
authors: Tomaszewski
authors: Jarogniew J
authors: JJ
authors: Luszczki
authors: Stanislaw J
authors: SJ
authors: Czuczwar
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000378:metabolism / Q000494:pharmacology; D000069059:Atorvastatin; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002220:Carbamazepine / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D004347:Drug Interactions; D004597:Electroshock / Q000009:adverse effects*; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008568:Memory / Q000187:drug effects; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010672:Phenytoin / Q000378:metabolism / Q000494:pharmacology*; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology*; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D014635:Valproic Acid / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D000927:Anticonvulsants; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D007211:Indoles; D011758:Pyrroles; D002220:Carbamazepine; D000077340:Fluvastatin; D014635:Valproic Acid; D010672:Phenytoin; D000069059:Atorvastatin